AMYOTROPHIC LATERAL SCLEROSIS (ALS)

This early-stage trial tests whether a daily supplement called HMB (beta-hydroxy-beta-methylbutyrate) is safe and can lower certain blood markers linked to ALS. One hundred adults with ALS will take 3 grams of HMB daily. Researchers will track changes in blood markers and functio…

This phase 3 trial tests whether adding masitinib to standard ALS treatment (riluzole) can slow the disease better than placebo plus riluzole. About 412 adults with ALS will take the drug or placebo for 48 weeks. The main goal is to measure changes in daily function and breathing…

This early-stage trial is testing a new gene therapy called SNUG01 for people with ALS, a disease that damages nerves controlling movement. The study will involve 21 adults and aims to check if the treatment is safe and tolerable. Researchers will also look for early signs that i…

This pilot study tests a non-invasive device that stimulates a nerve in the neck to see if it can increase how often people with ALS swallow and their urge to swallow. Up to 5 participants will receive supervised treatment sessions and be monitored with swallowing tests. The goal…

This study looks at whether giving people with ALS and their caregivers video recordings of their clinic visits helps them feel better and manage care more easily. About 800 participants (400 patient-caregiver pairs) from eight U.S. sites will be split into two groups: one gets s…

This study tests a mind-body program designed to help people recently diagnosed with ALS and their caregivers manage emotional distress. About 20 patient-caregiver pairs will try a 6-session coping intervention. The main goal is to see if the program is practical and well-liked, …

This pilot study will use ultrasound to measure diaphragm movement in 20 ALS patients, both while they breathe on their own and while using non-invasive ventilation (NIV). The goal is to see if ultrasound can detect changes in how the diaphragm works with and without the breathin…